Article History
Received: 23 April 2021
Accepted: 24 June 2021
First Online: 12 August 2021
Competing interests
: R.S.H. receives consulting fees from Abbvie Pharmaceuticals, ARMO Biosciences, AstraZeneca, Bayer HealthCare Pharmaceuticals, Bolt Biotherapeutics, Bristol-Myers Squibb, Candel Therapeutics, Cybrexa Therapeutics, eFFECTOR Therapeutics, Eli Lilly and Company, EMD Serono, Foundation Medicine, Genentech and Roche, Genmab, Gilead, Halozyme Therapeutics, Heat Biologics, I-Mab Biopharma, Immunocore, Infinity Pharmaceuticals, Loxo Oncology, Merck, Mirati Therapeutics, Nektar, Neon Therapeutics, NextCure, Novartis, Ocean Biomedical, Oncternal Therapeutics, Pfizer, Refactor Health, Ribbon Therapeutics, Sanofi, Seattle Genetics, Shire PLC, Spectrum Pharmaceuticals, STCubePharmaceuticals, Symphogen, Takeda, Tesaro, Tocagen, Ventana Medical Systems, WindMIL Therapeutics, Xencor. R.S.H. also receives research support from AstraZeneca, Eli Lilly and Company, Genentech and Roche, and Merck, and serves as a board member (non-executive, independent member) for Immunocore Holdings and Junshi Pharmaceuticals. C.B. is an employee and shareholder of Pfizer. M.W. declares no competing interests.